UK markets closed

Athira Pharma, Inc. (ATHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.95+0.57 (+4.64%)
As of 02:34PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 507.23M
Enterprise value 273.44M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.51
Enterprise value/revenue N/A
Enterprise value/EBITDA -5.92

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-49.22%
S&P500 52-week change 323.08%
52-week high 334.79
52-week low 38.88
50-day moving average 312.15
200-day moving average 314.48

Share statistics

Avg vol (3-month) 3443.74k
Avg vol (10-day) 3428.24k
Shares outstanding 537.35M
Implied shares outstanding 6N/A
Float 830.15M
% held by insiders 14.97%
% held by institutions 167.12%
Shares short (14 Nov 2021) 41.52M
Short ratio (14 Nov 2021) 42.38
Short % of float (14 Nov 2021) 44.71%
Short % of shares outstanding (14 Nov 2021) 44.06%
Shares short (prior month 14 Oct 2021) 41.07M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-11.04%
Return on equity (ttm)-15.52%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -53.97M
Net income avi to common (ttm)-46.25M
Diluted EPS (ttm)-1.37
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)235.78M
Total cash per share (mrq)6.31
Total debt (mrq)1.99M
Total debt/equity (mrq)0.59
Current ratio (mrq)25.46
Book value per share (mrq)9.00

Cash flow statement

Operating cash flow (ttm)-35.59M
Levered free cash flow (ttm)-28.12M